Revenue and Profitability - Revenue for Q3 2024 was CNY 35,783,445.19, a decrease of 25.93% year-over-year, and year-to-date revenue was CNY 226,570,852.23, down 59.69% compared to the same period last year[2] - Net profit attributable to shareholders for Q3 2024 was a loss of CNY 67,388,600.15, and year-to-date net profit was a loss of CNY 71,836,060.02, reflecting an increase in losses of 11,142.92% year-over-year[2] - Basic and diluted earnings per share for Q3 2024 were both -0.2457, reflecting a significant decline compared to the previous year[2] - Total operating revenue for the first three quarters of 2024 was ¥226,570,852.23, a decrease of 59.7% compared to ¥562,058,852.86 in the same period of 2023[14] - Net loss for the first three quarters of 2024 was ¥82,672,022.37, compared to a net profit of ¥998,459.62 in the same period of 2023, indicating a substantial decline in profitability[16] - The company's basic and diluted earnings per share for the first three quarters of 2024 were both -¥0.2623, compared to ¥0.0024 in 2023, highlighting a negative shift in earnings performance[17] Research and Development - R&D investment totaled CNY 25,419,547.01 in Q3 2024, an increase of 49.13% year-over-year, and accounted for 71.04% of revenue, up 35.75 percentage points[3] - R&D investment for the inhalation solution project increased significantly during the quarter, impacting overall R&D spending[7] - Research and development expenses for the first three quarters of 2024 were ¥26,325,369.38, down 58.8% from ¥63,925,857.68 in the same period of 2023, indicating a reduction in investment in innovation[15] Assets and Liabilities - Total assets as of the end of Q3 2024 were CNY 1,368,560,964.71, a decrease of 21.24% from the previous year[3] - Total current assets decreased from 1,290,011,027.37 RMB to 911,150,884.10 RMB, a decline of approximately 29.3%[11] - Total assets decreased from 1,737,536,466.45 RMB to 1,368,560,964.71 RMB, a decline of approximately 21.2%[12] - The total liabilities of the company as of the reporting date were ¥158,904,683.58, a decrease from ¥435,210,026.70 in the previous year, indicating improved financial stability[16] - Total current liabilities decreased from 429,441,961.38 RMB to 153,760,240.79 RMB, a decline of approximately 64.2%[12] Cash Flow - The net cash flow from operating activities for the year-to-date period was CNY 30,109,281.80, down 66.01% compared to the previous year[3] - The net cash flow from operating activities for the first three quarters of 2024 is ¥30,109,281.80, a decrease of 66.0% compared to ¥88,584,510.48 in the same period of 2023[18] - Total cash inflow from operating activities decreased to ¥270,074,284.83, down 56.9% from ¥626,379,760.43 year-on-year[18] - Cash outflow from operating activities also decreased to ¥239,965,003.03, a reduction of 55.5% compared to ¥537,795,249.95 in the previous year[18] - The net cash flow from investing activities for the first three quarters of 2024 is ¥66,336,194.76, compared to a negative cash flow of -¥8,277,653.84 in the same period of 2023[19] - The net cash flow from financing activities for the first three quarters of 2024 is -¥269,668,199.85, an improvement from -¥291,887,142.58 in the same period of 2023[19] Shareholder Information - Total number of common shareholders at the end of the reporting period is 9,069[9] - Hunan Pharmaceutical Development Investment Group Co., Ltd. holds 78,400,000 shares, accounting for 28.57% of total shares[10] - Guangzhou Qianyuan Investment Management Enterprise (Limited Partnership) holds 43,120,000 shares, accounting for 15.71% of total shares[10] Other Financial Metrics - The weighted average return on equity was -5.3007% for Q3 2024, a decrease of 3.21 percentage points year-over-year[3] - Non-recurring gains and losses for the year-to-date period amounted to CNY 16,774.42, with a total of CNY 517,510.33 for the year[5] - The company adjusted the prices of some core products to maintain market share, contributing to the decline in revenue[6] - Sales expenses decreased significantly to ¥63,868,011.29 in 2024 from ¥341,793,551.23 in 2023, reflecting a strategic shift in marketing expenditures[15] - The company reported a significant increase in credit impairment losses, amounting to -¥89,365,221.19 in 2024 compared to -¥41,990,781.12 in 2023, indicating rising credit risk[15] - Deferred income tax liabilities increased to ¥1,373,942.26 from ¥1,531,728.57, suggesting potential future tax obligations[16] - The ending balance of cash and cash equivalents as of the end of the third quarter of 2024 is ¥388,506,660.17, down from ¥501,891,678.69 at the end of the same period in 2023[19] - The company received ¥12,103,123.17 from other operating activities, a decrease from ¥17,234,332.14 in the previous year[18] - The company paid ¥40,924,775.62 in taxes, a decrease of 55.7% compared to ¥92,505,208.72 in the same period of 2023[18]

证券代码：688189 证券简称：南新制药 公告编号：2024-044 湖南南新制药股份有限公司 关于预挂牌转让全资子公司 100%股权的提示性公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 湖南南新制药股份有限公司（以下简称"公司"）拟通过湖南省联合产 权交易所有限公司（以下简称"湖南联交所"）预挂牌转让公司的全资子公司常 德臻诚医药科技有限公司（以下简称"常德臻诚"）100%股权。 本次预挂牌仅为信息预披露，不构成交易行为。交易对方、交易价格、 支付方式等交易主要内容目前尚无法确定，能否成交存在不确定性，敬请广大投 资者注意投资风险。 本次交易尚需根据常德臻诚 100%股权的审计和评估情况履行相应的审 批程序并及时履行信息披露义务。 本次交易预计不构成《上市公司重大资产重组管理办法》规定的重大资 产重组事项。 一、交易概述 （一）常德臻诚基本情况 1、企业名称：常德臻诚医药科技有限公司 按照国资监管的相关规定，本次交易在进行预挂牌后，还需进行正式挂牌， 交易条件以正式挂牌为准。本次预挂牌后，公司将 ...

证券代码：688189 证券简称：南新制药 湖南南新制药股份有限公司 投资者关系活动记录表 编号：2024-001 | --- | --- | --- | |----------------|-------------------------------|----------------------------------------------------| | | | | | | □ 特定对象调研 | □ 分析师会议 | | | □ 媒体采访 | □ 业绩说明会 | | 投资者关系 | □ 新闻发布会 | □ 路演活动 | | 活动类别 | □现场参观 | √ 其他 （ 湖南辖区 2024 年度投资者 | | | | 网上集体接待日活动） | | 参与单位名称 | 线上参加湖南辖区 2024 | 年度投资者网上集体接待日活动的投资者 | | 及人员姓名 | | | | 时间 | 2024 年 10 月 10 日 | 14:00-17:00 | | 地点 | 长沙市芙蓉区解放东路 300 | 号华天大酒店 C 座三楼湖南厅 | | 上市公司接待 | 董事会秘书：李旋 | | | 人员姓名 | 证券事务代表： ...

证券代码：688189 证券简称：南新制药 公告编号：2024-042 湖南南新制药股份有限公司（以下简称"公司"）于 2023 年 12 月 20 日召开 第二届董事会第七次会议，审议通过了《关于以集中竞价交易方式回购公司股份 方案的议案》，同意公司以不低于人民币 500 万元（含）且不超过人民币 1,000 万 元（含）的自有资金或自筹资金，通过集中竞价交易方式回购公司人民币普通股 （A 股）股票，在未来适宜时机全部用于股权激励或员工持股计划，回购价格不超 过人民币 15.85 元/股（含），回购期限为自公司董事会审议通过本次回购股份方 案之日起 12 个月内。具体情况详见公司于 2023 年 12 月 21 日、12 月 27 日在上海 证券交易所网站（www.sse.com.cn）披露的《关于以集中竞价交易方式回购公司 股份方案的公告》（公告编号：2023-067）、《关于以集中竞价交易方式回购公司股 份的回购报告书》（公告编号：2023-069）。 二、 回购实施情况 1、2024 年 1 月 12 日，公司首次实施回购股份，并于 2024 年 1 月 13 日披露 了首次回购股份情况，具体内容详见 ...

Financial Performance - The company reported a total operating revenue of 190.79 million yuan, a decrease of 62.86% compared to the same period last year[3]. - The total profit for the period was -3.95 million yuan, representing a decline of 113.78% year-over-year[3]. - The net profit attributable to shareholders was -4.45 million yuan, down 115.66% from the previous year[3]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was -4.95 million yuan, a decrease of 114.33% year-over-year[3]. - The company reported a revenue of CNY 190,787,407.04 for the first half of 2024, a decrease of 62.86% compared to the same period last year[12]. - The net profit attributable to shareholders was CNY -4,447,459.88, representing a decline of 115.66% year-on-year[12]. - The basic earnings per share for the period was CNY -0.0162, down 115.65% from CNY 0.1035 in the same period last year[13]. - The company's total assets decreased by 11.2% to CNY 1,542,955,188.22 compared to the end of the previous year[12]. - The weighted average return on equity was -0.34%, a decrease of 2.48 percentage points compared to the previous year[13]. - The company achieved operating revenue of CNY 190.79 million in the first half of 2024, a decrease of 62.86% compared to the same period last year[18]. - The total profit for the period was CNY -3.95 million, representing a decline of 113.78% year-over-year[18]. - The net profit attributable to shareholders was CNY -4.45 million, down 115.66% from the previous year[18]. Research and Development - The company has 20 new products in development, including 7 innovative drug projects and 12 generic drug projects[18]. - Research and development expenses accounted for 16.68% of revenue, an increase of 6.56 percentage points year-on-year[13]. - The company achieved a total R&D investment of CNY 31.83 million, a decrease of 38.79% compared to the same period last year[29]. - Capitalized R&D investment increased significantly to CNY 17.03 million, up 505.26% year-on-year[29]. - The company obtained 1 new invention patent during the reporting period, bringing the total to 28 authorized invention patents[28]. - The company has developed a core platform for drug design and discovery, leading to the identification of multi-target kinase inhibitors with intellectual property rights[25]. - The company has launched the first domestic anti-influenza 1.1 class innovative drug, which is now included in the national medical insurance[19]. - The company is enhancing its product lines in cardiovascular diseases and pain relief, with several products already on the market and more in development[20]. - The company has established a comprehensive product line covering various administration routes for influenza and related diseases, including injection, oral, and inhalation forms[19]. Sales and Marketing Strategy - The company adjusted its sales strategy and reduced prices for some core products to maintain market share, impacting revenue and gross margin negatively[3]. - The sales strategy includes professional promotion and collaboration with academic institutions to improve clinical solutions and gather feedback for product enhancement[21]. - The average price reduction for products involved in the national volume-based procurement was over 50%, significantly impacting sales prices and volumes[46]. - The company has established a nationwide marketing network with dedicated personnel in nearly thirty provinces, supporting stable sales growth and facilitating the commercialization of new drugs[39]. Financial Management and Governance - The board of directors confirmed the authenticity, accuracy, and completeness of the financial report[2]. - The report has not been audited[2]. - There are no significant non-operating fund occupations by controlling shareholders or related parties[2]. - The company has committed to maintaining the independence of its operations, ensuring it has the necessary assets, personnel, qualifications, and capabilities for independent business activities[72]. - The company guarantees that its senior management will not hold positions in other enterprises controlled by it, ensuring a complete and independent labor, personnel, and compensation management system[72]. - The company has established a commitment to avoid significant related-party transactions with Nanjing Pharmaceutical, ensuring fair and reasonable pricing in any necessary transactions[74]. - The company has pledged to compensate Nanjing Pharmaceutical for any direct or indirect losses if it fails to comply with its commitments regarding competition[74]. - The company guarantees strict compliance with laws and regulations, ensuring no misuse of funds or assets, and will bear compensation responsibility for any losses caused by violations[76]. Environmental Responsibility - The company invested 87.19 million CNY in environmental protection during the reporting period[59]. - The company has a wastewater treatment facility with a processing capacity of 600 tons per day, operational since March 2017[64]. - The company has implemented an online monitoring system for pollutants, ensuring real-time tracking of emissions[67]. - The company has committed to reducing carbon emissions through energy-saving measures, although direct CO2 emissions are not applicable[70]. - The company has reported a total of 0.75 tons of non-hazardous sludge disposed of from the wastewater treatment station[63]. - The company has established environmental protection goals and plans, ensuring compliance with national and local regulations[69]. Legal and Compliance - The company received a regulatory warning from the Shanghai Stock Exchange for inaccurate performance forecasts, leading to a commitment to improve data accuracy and compliance with disclosure rules[89]. - The company has submitted a rectification report to the Shanghai Stock Exchange, detailing measures to enhance accounting accuracy and establish a performance forecast data review mechanism[89]. - There were no significant lawsuits or arbitration matters during the reporting period, indicating a stable legal environment for the company[90]. - The company has not engaged in any non-operating fund occupation by controlling shareholders or related parties during the reporting period[87]. Shareholder Information - The total number of ordinary shareholders as of the end of the reporting period was 9,222[103]. - The largest shareholder, Hunan Pharmaceutical Development Investment Group Co., Ltd., holds 78,400,000 shares, representing 28.57% of the total shares[104]. - The second-largest shareholder, Guangzhou Qianyuan Investment Management Partnership, holds 43,120,000 shares, representing 15.71% of the total shares[104]. - The company did not experience any changes in the total number of ordinary shares or share capital structure during the reporting period[102]. - The company has not disclosed any significant matters or changes in shareholder structure during the reporting period[101]. Cash Flow and Liquidity - The net cash flow from operating activities was CNY 62,161,424.57, an increase of 18.53% compared to the previous year[12]. - The company's cash and cash equivalents decreased by 20.54% year-on-year, primarily due to loan repayments[52]. - The proportion of accounts receivable to total assets increased to 32.65%, compared to 31.31% in the previous year[52]. - The company’s short-term borrowings decreased by 51.97% year-on-year, reflecting a reduction in bank loans[52]. - Cash flow from operating activities for the first half of 2024 was CNY 62,161,424.57, an increase from CNY 52,442,313.53 in the same period of 2023[119]. Asset Management - The company's total assets decreased to ¥1,542,955,188.22 from ¥1,737,536,466.45 as of December 31, 2023, representing a decline of approximately 11.2%[109]. - Current assets totaled ¥1,094,429,506.17, down from ¥1,290,011,027.37, indicating a decrease of about 15.2%[108]. - Total liabilities decreased to ¥254,260,598.42 from ¥435,210,026.70, a reduction of about 41.5%[110]. - The company's equity attributable to shareholders decreased to ¥1,305,671,182.35 from ¥1,318,116,026.60, a decline of approximately 0.9%[110]. Investment and Capital Management - The total amount of funds raised through the initial public offering was CNY 122,290 million, with a net amount of CNY 113,528.23 million after deducting issuance costs[95]. - The company has invested CNY 2,008.14 million in innovative drug research and development, achieving a cumulative investment of CNY 14,816.68 million, which is 36.17% of the planned investment[96]. - The marketing channel network upgrade project has a cumulative investment of CNY 97.50 million, with a progress rate of only 0.81% due to delays caused by significant health events and economic conditions[97]. - The company has allocated CNY 21,503,956.02 to surplus reserves, reflecting prudent financial management[134].

湖南南新制药股份有限公司 2024 年度提质增效重回报专项行动方案的 半年度评估报告 湖南南新制药股份有限公司（以下简称"公司"）为积极响应落实关于上海证券交 易所开展科创板上市公司"提质增效重回报"专项行动的倡议，落实"以投资者为本" 的理念，维护公司全体股东的利益，于 2024 年 4 月 30 日发布了《2024 年度"提质增 效重回报"行动方案》（以下简称"行动方案"）。此行动方案为公司 2024 年度提质增 效重回报行动明确了工作方向，公司根据行动方案内容，积极开展和落实各项工作， 现将 2024 年半年度的主要工作成果报告如下： 一、 行动方案执行情况 2024 年半年度，公司研发投入合计 3,183.19 万元，占营业收入比例为 16.68%， 研发投入占营业收入比例较上一年同期增加 6.56 个百分点,新增获得发明专利 1 项； 截至 2024 年 6 月 30 日，公司拥有研发人员 74 名（其中博士研究生 4 名，硕士研究 生 12 名），占公司总人数的 20.44%。公司累计获得授权发明专利 28 项，累计获得授 权软件著作权 4 项。 目前，公司多个研发项目正在有序推进。公司布洛芬混悬 ...

证券代码：688189 证券简称：南新制药 公告编号：2024-039 湖南南新制药股份有限公司 关于自愿披露头孢泊肟酯干混悬剂通过仿制药质量和 疗效一致性评价的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 近日，湖南南新制药股份有限公司（以下简称"公司"）的子公司广州南新 制药有限公司收到国家药品监督管理局核准签发的关于头孢泊肟酯干混悬剂的 《药品补充申请批准通知书》。现将相关情况公告如下： 一、药品基本信息 1、药品名称：头孢泊肟酯干混悬剂 2、剂型：干混悬剂 上呼吸道感染、下呼吸道感染、单纯性泌尿道感染、单纯性皮肤和皮肤软组织感 染、急性单纯性淋球菌性尿道炎和子宫颈炎、由奈瑟氏淋球菌引起的肛周炎等。 三、对公司的影响及风险提示 根据国家相关政策，通过仿制药质量和疗效一致性评价的药品品种在医保支 付及医疗机构采购等领域将获得更大的支持力度。公司的头孢泊肟酯干混悬剂通 过仿制药质量和疗效一致性评价将有利于该产品未来的市场销售和市场竞争，同 时为公司后续一致性评价产品研究积累了丰富的经验，进一步提升了公司整体研 发 ...

证券代码：688189 证券简称：南新制药 公告编号：2024-037 湖南南新制药股份有限公司 关于核心技术人员退休离任暨新增认定核心技术人员的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 2024 年 8 月 28 日，公司召开第二届董事会第十一次会议，审议通过了 《关于新增认定核心技术人员的议案》，新增认定吴弼东先生、罗军奇先生为公 司核心技术人员。 一、核心技术人员退休离任的具体情况 公司核心技术人员王兴旺先生因已届法定退休年龄，已办理完成退休离任手 续。退休离任后，王兴旺先生不再担任公司任何职务。公司及董事会对王兴旺先 生作为核心技术人员期间的勤勉工作和为公司发展做出的贡献表示衷心感谢！ （一）核心技术人员的具体情况 王兴旺先生：1959 年 7 月出生，中国国籍，无境外永久居留权，中国科学院 上海细胞所肿瘤生物治疗学博士后。1980 年 2 月至 2000 年 2 月就职于扬州大学 医学院，2000 年 3 月至 2005 年 12 月就职于金陵药业股份有限公司，2006 年 1 月至 2010 年 9 ...